These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38613194)
1. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA::NTRK1-rearranged soft-tissue sarcoma cell model. Chen Y; Steiner S; Hagedorn C; Kollar S; Pliego-Mendieta A; Haberecker M; Plock J; Britschgi C; Planas-Paz L; Pauli C J Pathol; 2024 Jun; 263(2):257-269. PubMed ID: 38613194 [TBL] [Abstract][Full Text] [Related]
2. Myxoid Spindle Cell Sarcoma With So YK; Chow C; To KF; Chan JKC; Cheuk W Int J Surg Pathol; 2020 Aug; 28(5):574-578. PubMed ID: 32050835 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers. Fuse MJ; Okada K; Oh-Hara T; Ogura H; Fujita N; Katayama R Mol Cancer Ther; 2017 Oct; 16(10):2130-2143. PubMed ID: 28751539 [No Abstract] [Full Text] [Related]
4. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions. Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002 [TBL] [Abstract][Full Text] [Related]
5. Larotrectinib followed by selitrectinib in a novel Goh XN; Seng MS; Loh AHP; Gupta A; Chang KTE; Iyer P J Oncol Pharm Pract; 2021 Mar; 27(2):485-489. PubMed ID: 32693686 [TBL] [Abstract][Full Text] [Related]
6. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report. Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851 [TBL] [Abstract][Full Text] [Related]
7. Foretinib Overcomes Entrectinib Resistance Associated with the Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555 [No Abstract] [Full Text] [Related]
8. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells. Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931 [TBL] [Abstract][Full Text] [Related]
9. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing. Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039 [TBL] [Abstract][Full Text] [Related]
11. Detecting and Targeting NTRK Fusions in Cancer in the Era of Tumor Agnostic Oncology. Rohrberg KS; Lassen U Drugs; 2021 Mar; 81(4):445-452. PubMed ID: 33400240 [TBL] [Abstract][Full Text] [Related]
12. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955 [TBL] [Abstract][Full Text] [Related]
13. An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Doebele RC; Davis LE; Vaishnavi A; Le AT; Estrada-Bernal A; Keysar S; Jimeno A; Varella-Garcia M; Aisner DL; Li Y; Stephens PJ; Morosini D; Tuch BB; Fernandes M; Nanda N; Low JA Cancer Discov; 2015 Oct; 5(10):1049-57. PubMed ID: 26216294 [TBL] [Abstract][Full Text] [Related]
14. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions. Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors. Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984 [TBL] [Abstract][Full Text] [Related]
16. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295 [TBL] [Abstract][Full Text] [Related]
17. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue Sarcomas Using DNA/RNA-based Clinical Sequencing. Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853 [TBL] [Abstract][Full Text] [Related]
18. Paediatric and adult soft tissue sarcomas with NTRK1 gene fusions: a subset of spindle cell sarcomas unified by a prominent myopericytic/haemangiopericytic pattern. Haller F; Knopf J; Ackermann A; Bieg M; Kleinheinz K; Schlesner M; Moskalev EA; Will R; Satir AA; Abdelmagid IE; Giedl J; Carbon R; Rompel O; Hartmann A; Wiemann S; Metzler M; Agaimy A J Pathol; 2016 Apr; 238(5):700-10. PubMed ID: 26863915 [TBL] [Abstract][Full Text] [Related]
19. Tropomyosin receptor kinase inhibitors in the management of sarcomas. Wilding CP; Loong HH; Huang PH; Jones RL Curr Opin Oncol; 2020 Jul; 32(4):307-313. PubMed ID: 32541318 [TBL] [Abstract][Full Text] [Related]
20. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]